October 2025 in “Pharmaceutics” This study highlights the clinical potential of microneedles as an innovative transdermal drug delivery system for treating various skin diseases with minimal pain and high patient compliance.
August 2025 in “Drug Design Development and Therapy” This review article examines current drugs for androgenetic alopecia, focusing on their mechanisms and clinical efficacy, noting that while finasteride and minoxidil are commonly approved treatments, new drugs targeting different pathogenic pathways have emerged, offering a broader understanding and reference for AGA treatment options.
7 citations
,
July 2025 in “International Journal of Dermatology” This meta-analysis found that patients with alopecia areata have significantly higher odds of also having immune-mediated diseases such as atopic dermatitis, autoimmune thyroiditis, inflammatory bowel disease, systemic lupus erythematosus, and vitiligo, suggesting a need for comprehensive screening and interdisciplinary management.
June 2025 in “Stem Cell Research & Therapy” This review highlights recent advancements in androgenetic alopecia treatment, focusing on the dysregulated signaling pathways involved in hair follicle regeneration and exploring innovative therapeutic strategies, including small molecule modulators and gene editing technologies, which show promise in preclinical models.
May 2025 in “Skin Appendage Disorders” This review reports that psoriatic alopecia, a type of hair loss linked to psoriasis, is difficult to diagnose and often resistant to conventional treatments, highlighting the need for further research into its immune-related mechanisms and personalized treatment approaches for better management.
4 citations
,
May 2025 in “Frontiers in Immunology” This review examines the mechanisms of Janus kinase inhibitors in treating alopecia areata and evaluates their efficacy and safety, but reports no new clinical results.
April 2025 in “Acta Dermato Venereologica” This review evaluates 21 studies on minoxidil-induced allergic contact dermatitis, finding that some patients with contact dermatitis symptoms like erythema and pruritus are sensitized to minoxidil or its vehicle components and should consider patch testing and alternative formulations for proper management.
February 2025 in “PLoS ONE” This study provides an overview of androgenetic alopecia in the USA, highlighting social determinants, differences in onset between genders, and how management varies by age and gender.
February 2025 in “Experimental Cell Research” In this laboratory study, the researchers found that combining dermal papilla cell-derived exosomes with collagenous sequences significantly enhanced hair follicle stem cell migration and proliferation, highlighting a potential strategy for hair regeneration through modulation of the hsa-novel-238a-CASP9 axis.
December 2024 in “Asian Journal of Medical Sciences” This study observed that a majority of female patients with chronic telogen effluvium had low serum ferritin levels without signs of clinical anemia, suggesting a possible link between low iron stores and hair loss.
4 citations
,
November 2024 in “International Journal of Dermatology” This study examines the link between testosterone use and hair health in males, stressing the importance of developing guidelines for safe usage due to associated health risks like liver toxicity, gynecomastia, and hair loss.
September 2024 in “Current Oncology” This review discusses the common occurrence of docetaxel-induced hair loss in cancer patients, including permanent cases, and highlights current and experimental strategies like scalp cooling, minoxidil, and new clinical trials for managing and preventing this side effect.
3 citations
,
September 2024 in “Dermatology and Therapy” Previous alopecia areata treatments do not affect the long-term effectiveness of ritlecitinib.
August 2024 in “Journal of Cosmetic Dermatology” This study explored the effectiveness of injectable treatments for androgenetic alopecia, finding that dutasteride and growth factor formulations achieved clinically significant results compared to controls like saline and topical minoxidil, within selected trials from 2000 to 2023.
August 2024 in “Frontiers in Nutrition” In this study, higher dietary antioxidant intake was linked to a decreased risk of androgenic alopecia, while higher dietary inflammatory intake increased the risk, especially among women, although these links were influenced by metabolic syndrome presence.
1 citations
,
July 2024 in “Indian Journal of Sexually Transmitted Diseases and AIDS” In this study, a 38-year-old male with syphilis-related mixed pattern alopecia showed marked hair regrowth and resolution of postauricular lymphadenopathy after treatment with benzathine penicillin, suggesting that lymph node and hair examinations, along with trichoscopy, can aid in the diagnosis of alopecia syphilitica.
13 citations
,
February 2024 in “World Journal of Stem Cells” This review examined the role of molecular markers in isolating and tracing hair follicle stem cells, emphasizing their regulatory roles as revealed by single-cell transcriptomics data.
This study found that androgenetic alopecia patients exhibited impaired arginine metabolism in balding hair follicles, suggesting that arginine supplementation may help preserve hair growth by counteracting mTOR signaling pathway disruption and offering potential as a treatment strategy.
November 2023 in “Frontiers in cell and developmental biology” This source reviews mechanisms and existing treatments for hair aging, highlighting factors like oxidative stress and DNA repair defects that affect hair follicle and stem cell function, and discusses research limitations and future directions in the field.
6 citations
,
November 2023 in “JCI Insight” In mouse models, this study showed that transplanted dermal papilla and dermal sheath cells can integrate into hair follicles, promoting hair growth and extended anagen phases, with their effectiveness influenced by factors such as immune response and cell passage number.
November 2023 in “Clinical, Cosmetic and Investigational Dermatology” This study found that both oral and topical formulations of VISPOTM, a saw palmetto oil, significantly reduced hair fall and increased hair density in subjects with androgenetic alopecia, with no serious adverse effects observed.
This study compared the safety and effectiveness of 5% cetosomal minoxidil to 5% alcohol-based minoxidil in Indian men with androgenetic alopecia, finding that cetosomal minoxidil had improved safety and similar efficacy, making it a potentially better option for those sensitive to alcohol-based formulations.
August 2023 in “Journal of Cosmetic Dermatology” This study found that intradermal QR678 Neo® therapy improved scalp condition in men and women with seborrheic dermatitis unresponsive to standard treatments, reducing flaking and inflammation after eight sessions, with high patient satisfaction reported.
August 2023 in “Stem Cell Research & Therapy” In this study on male androgenetic alopecia, the researchers reported significant increases in hair count, density, and thickness with minimal side effects over 6 weeks using adipose-derived stem cell conditioned media and minoxidil, but found no significant differences between concentrated and non-concentrated treatments.
This study reviewed existing literature to demonstrate that thyroid disorders have a significant and underestimated impact on hair loss, highlighting gaps in current knowledge and the need for further research to better diagnose and manage hair disorders linked to thyroid dysfunction.
July 2023 in “JAAD International” This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.
This study found that garlic exosomes induced hair growth in rats by increasing anagen follicle counts and activating multiple signaling pathways, including Wnt-1, β-catenin, and TGF-β1.
1 citations
,
July 2023 in “Cancers” In this multicentric retrospective study, researchers reported that cutaneous adverse events were common among advanced breast cancer patients treated with cyclin-dependent kinase inhibitors (CDK4/6i), generally mild, and manageable with topical treatments, though in some cases, they led to treatment discontinuation.
3 citations
,
June 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” This article discusses the clinical spectrum and pathobiology of radiotherapy-induced alopecia and reports no new research findings, highlighting potential pathways for future targeted RIA management.
4 citations
,
March 2023 in “Current Oncology” This study reviews current methods and emerging approaches to prevent and treat chemotherapy-induced hair loss, reporting that evidence-based research is needed to validate effective strategies, which could enhance cancer patients’ quality of life and treatment compliance.
March 2023 in “International Journal of Trichology” This study found that a combination of topical 5% minoxidil and 0.25% finasteride was more effective at improving hair density and satisfaction in men with androgenetic alopecia than either treatment alone over 24 weeks.
14 citations
,
February 2023 in “Frontiers in immunology” This review discusses the range of cutaneous immune-related adverse events induced by immune checkpoint inhibitors and the proposed mechanisms underlying these skin reactions, but reports no new clinical results.
February 2023 in “Journal of Drugs in Dermatology” In this literature review, researchers found evidence that topical melatonin may improve scalp hair growth, density, and thickness in patients with androgenetic alopecia, especially in men.
104 citations
,
January 2023 in “Journal of Clinical Medicine” This review evaluates the hair cycle's phases and the factors influencing the transition between anagen and telogen, advocating for a holistic approach to addressing hair loss, though no specific results are reported.
10 citations
,
January 2023 in “Skin Appendage Disorders” This review discusses the histological features and diagnostic challenges of alopecia areata and emphasizes the need for genetic research to develop future therapeutics; it reports no new clinical findings.
January 2023 in “European endocrinology” This review explores the association between alopecia and thyroid autoimmune disease, also highlighting a linked increased risk of thyroid cancer, but presents no new clinical findings.
January 2023 in “Skin appendage disorders” This case report describes a patient who experienced proton-induced alopecia after proton therapy for a frontal meningioma, which was effectively treated with topical minoxidil, resulting in full hair regrowth after 4 months.
1 citations
,
January 2023 in “PubMed” This systematic review and meta-analysis found limited, low-quality evidence suggesting that platelet-rich plasma injections may increase hair density in patients with androgenetic alopecia compared to saline, but results were inconclusive for alopecia areata.
This review discusses the role of the Wnt/β-catenin pathway in hair follicle development and how natural products that activate this signaling could be used to treat hair loss, but it reports no new experimental results.
November 2022 in “Molecular Pharmaceutics” This study found that intradermal injection of a cell-penetrating, AR-targeting asiRNA promoted hair growth and reduced androgen receptor expression in mouse models of androgenetic alopecia, suggesting its therapeutic potential.
1 citations
,
October 2022 in “Current Opinion in Endocrinology, Diabetes and Obesity” This review discusses the diagnosis, management, and clinical challenges of female pattern hair loss in PCOS patients but reports no new clinical findings, highlighting the need for further research and multidisciplinary care.
September 2022 in “Journal of Cosmetic Dermatology” This article discusses the efficacy of different derma roller sizes compared to topical applications for administering QR678 Neo® in treating androgenetic alopecia, but provides no new clinical results.
21 citations
,
May 2022 in “Frontiers in Cell and Developmental Biology” This review covers the structure, development, cycle, and molecular regulation of hair follicles but does not report new results, aiming to offer insights for addressing hair follicle-related diseases.
25 citations
,
February 2022 in “JAAD International” This review analyzed data on alopecia types associated with COVID-19, suggesting androgenetic alopecia may be a risk factor for severe COVID-19, while telogen effluvium often follows infection and alopecia areata tends to relapse in those with preexisting disease.
2 citations
,
January 2022 in “Journal of Cosmetic Dermatology” This study found that intradermal administration of QR678 Neo® significantly reduced hair fall and improved hair growth in patients with androgenetic alopecia and female pattern hair loss, with no side effects reported during long-term follow-up.
5 citations
,
December 2021 in “Journal of Cosmetic Dermatology” In this study of 20 female patients with Covid-19-induced persistent Telogen Effluvium, intra-dermal QR678 Neo® treatments led to significant reductions in hair fall and increases in hair growth and density, sustained even post-therapy.
4 citations
,
November 2021 in “Journal of Cosmetic Dermatology” The researchers reported that QR678 Neo® combined with intralesional steroids significantly improved hair regrowth and patient satisfaction in treating alopecia areata compared to steroids alone.
2 citations
,
November 2021 in “ACG Case Reports Journal” This case study reports that tofacitinib effectively treated alopecia areata in a patient with Crohn's disease and maintained her Crohn's disease management.
30 citations
,
October 2021 in “Scientific Reports” This study found that human scalp hair follicles can internally operate a Cori cycle, synthesize glycogen in the presence of lactate, and modulate growth through glycogen phosphorylase activity.
11 citations
,
October 2021 in “Journal of The European Academy of Dermatology and Venereology” This study found that topical finasteride significantly increased hair count in men with androgenetic alopecia compared to placebo while maintaining similar efficacy to oral finasteride but with lower systemic exposure and a reduced impact on serum DHT levels, potentially minimizing sexual side effects.
10 citations
,
September 2021 in “JAMA Dermatology” This study reports that persistent chemotherapy-induced alopecia in breast cancer patients frequently resembles androgenetic alopecia, and treatment with minoxidil, alone or with antiandrogens, improved hair density in many cases.
14 citations
,
September 2021 in “Journal of Inflammation Research” This study suggests that female patients with alopecia areata, especially those with nail abnormalities and atopic diseases, may have higher rates of coexisting autoimmune diseases.
3 citations
,
April 2021 in “Journal of Cosmetic Dermatology” Combination therapy with QR 678 Neo and 5% Minoxidil is most effective for male hair loss.
4 citations
,
April 2021 in “Journal of Cosmetic Dermatology” This study found that both intradermal injection and derma roller techniques for QR678Neo® hair regrowth therapy improved androgenetic alopecia symptoms, with intradermal injections showing non-significantly better video-microscopic outcomes but more pain and erythema associated with derma rollers.
23 citations
,
January 2021 in “Journal of Dermatological Science” This review describes the diagnosis and management challenges of telogen effluvium, a type of hair loss triggered by physiological stress, and summarizes current understanding of its mechanisms and treatments while recommending future research directions.
3 citations
,
January 2021 in “Skin appendage disorders” This case report describes how trichoscopy helped diagnose tinea capitis disguised as female pattern hair loss in cases of endothrix infection, highlighting its usefulness in avoiding misdiagnosis.
4 citations
,
August 2020 in “Journal of Cosmetic Dermatology” In this study, QR678® and QR678 Neo® injections significantly improved hair density and thickness in women with PCOS-related alopecia over eight sessions, with effects lasting over a year.
7 citations
,
August 2020 in “Plastic and reconstructive surgery. Global open” In this study, QR 678 and QR 678 Neo formulations containing growth factors and peptides were found to be safe in vitro and promoted hair growth in vivo in an animal model, suggesting their potential as treatments for alopecia, including secondary alopecia post-chemotherapy.
86 citations
,
July 2020 in “International Journal of Molecular Sciences” This review discusses the role of Wnt/β-catenin signaling in hair follicle regeneration and highlights recent progress in developing hair loss treatments targeting this pathway, but reports no new clinical results.
40 citations
,
May 2020 in “Cureus” This review discusses the causes, diagnosis, and treatment of telogen effluvium and reports no new clinical findings; the authors underscore the importance of identifying and eliminating causative factors.
5 citations
,
May 2020 in “Clinical and Experimental Dermatology” This correspondence discusses clascoterone as a potential new treatment for androgenetic alopecia but reports no clinical results.
14 citations
,
April 2020 in “Journal of Cosmetic Dermatology” In this study, intradermal injections of QR678 were found to significantly reduce hair fall in men with androgenetic alopecia over 6 months, with superior improvements in hair density and thickness compared to PRP.
15 citations
,
April 2020 in “Journal of The American Academy of Dermatology” In this study, intradermal injection of botulinum toxin was associated with increased hair growth in men with androgenetic alopecia through the suppression of TGF-β1 secretion from dermal papilla cells.
January 2020 in “Jornal Vascular Brasileiro” This review discusses the mechanisms behind alopecia during anticoagulation therapy and current treatments but reports no new clinical results.
17 citations
,
January 2020 in “Skin appendage disorders” This review suggests that the Mediterranean diet, protein-rich diets, and soy may support hair health in nonscarring alopecias like androgenetic alopecia.
26 citations
,
December 2019 in “Neurobiology of Stress” This review discusses adverse effects of 5 alpha-reductase inhibitors, particularly persistent side effects such as post-finasteride syndrome, and highlights the need for further investigation.
49 citations
,
November 2019 in “Archives of Dermatological Research” 
16 citations
,
June 2019 in “International Journal of Women's Dermatology” This study found that type 2 diabetes was associated with a higher risk of severe central scalp hair loss in African American women.
13 citations
,
April 2019 in “Seizure” This review found that valproic acid treatment significantly increases the risk of alopecia compared to other drugs, regardless of dose or treatment duration.
February 2019 in “PubMed” This study found that 29.4% of patients treated with methotrexate for non-hair-related conditions experienced increased hair loss, with more frequent reports among women.
19 citations
,
January 2019 in “International Journal of Trichology” This consensus paper reviews expert opinions on treating telogen effluvium but reports no new clinical findings.
148 citations
,
December 2018 in “Journal of autoimmunity” This review discusses genetic and environmental factors contributing to autoimmunity in alopecia areata and reports no new clinical findings, emphasizing the need for further study on its aetiology and pathophysiology.
134 citations
,
December 2018 in “Dermatology and Therapy” This review discusses the potential role of vitamins and minerals in managing non-scarring alopecia but reports no clinical results; the authors advocate for further controlled trials to explore these relationships.
49 citations
,
December 2018 in “JAAD case reports” This case report describes a patient who developed alopecia after 18 weeks of treatment with dupilumab for atopic dermatitis.
76 citations
,
August 2018 in “International Journal of Cosmetic Science” This review discusses the use of Dermal Papilla cells as in vitro models for studying hair growth modulators, emphasizing their role in aiding the development of new hair treatments, but reports no new clinical results.
5 citations
,
August 2018 in “European Psychiatry” In this large multicenter study, severe hair loss related to psychotropic drug treatment was very rare but occurred more frequently in female patients, with valproic acid showing the highest risk.
45 citations
,
August 2018 in “Stem Cells International” This article reviews the potential of adipose-derived and Wharton’s jelly stem cells in alopecia treatment but presents no new clinical findings, highlighting their potential benefits and limitations in regenerative medicine.
3 citations
,
July 2018 in “JAAPA” This article reviews how to identify and manage androgenic alopecia caused by hormonal contraceptives but reports no new clinical findings.
8 citations
,
January 2018 in “Middle East Journal of Digestive Diseases” This case report describes a middle-aged man with alopecia universalis and ulcerative colitis, where hair regrowth occurred following treatment with azathioprine and mesalamine.
7 citations
,
May 2017 in “Research and Practice in Thrombosis and Haemostasis” This case report observed that a 20-year-old female with recurrent DVTs experienced reversible alopecia with various anticoagulants, except fondaparinux which allowed long-term treatment without this side effect.
178 citations
,
April 2017 in “Journal of The American Academy of Dermatology” This systematic review and meta-analysis found that minoxidil, finasteride, and low-level laser light therapy significantly improve hair growth in men with androgenetic alopecia, while minoxidil is also effective for women, compared to placebo.
153 citations
,
March 2017 in “Endocrine” This review examines recent advances in understanding the pathophysiology and molecular mechanisms of androgenetic alopecia, highlighting two major genetic risk loci, but does not report new clinical findings.
56 citations
,
March 2017 in “Journal of the American Academy of Dermatology” Alopecia areata patients often have eczema, thyroid issues, vitamin-D deficiency, and anemia.
6 citations
,
February 2017 in “Case Reports in Dermatology” This case report highlights that hair loss, though common in the general population, may be a rare presenting symptom of Cushing's disease, as observed in a woman with multiple dermatological signs of the condition.
79 citations
,
January 2017 in “Dermatology practical & conceptual” This article addresses the need to screen for nutrient deficiencies in patients with hair loss but reports no new findings, noting that supplementation without deficiency may not be beneficial and could pose risks.
25 citations
,
January 2017 in “International Journal of Trichology” This study found that nutritional deficiencies, particularly in amino acids and certain micronutrients, are common in individuals with hair loss across all types of alopecia.
21 citations
,
January 2017 in “Skin Pharmacology and Physiology” In this noninferiority study, researchers found that a 0.2% caffeine-based topical liquid was not less effective than 5% minoxidil solution in improving hair growth in men with androgenetic alopecia over six months.
32 citations
,
July 2016 in “PubMed” This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.
31 citations
,
January 2016 in “Drugs - Real World Outcomes” This review discusses the potential link between direct oral anticoagulants and hair loss, suggesting DOACs may not be a suitable alternative for patients with alopecia from traditional anticoagulants; however, no clinical results are reported.
10 citations
,
April 2015 in “PubMed” This study found that rosemary oil and minoxidil 2% both increased hair count equally in patients with androgenetic alopecia after 6 months, with more scalp itching seen in the minoxidil group.
3 citations
,
January 2015 in “Case reports in psychiatry” This case report describes a 21-year-old male who experienced sertraline-induced diffuse hair loss that improved after discontinuing the medication.
54 citations
,
December 2014 in “Wound Repair and Regeneration” This study observed that autologous PRP and PDRN injections improved hair thickness and density in women with pattern hair loss, with combined therapy showing greater improvement in thickness than PDRN alone.
184 citations
,
November 2014 in “Developmental Cell” This study identifies a bipotent stem cell in adult hair follicles that self-renews and contributes to dermal sheath and papilla cell populations, potentially aiding hair regrowth after injury, disease, or aging.
223 citations
,
January 2014 in “International Journal of Molecular Sciences” This article reviews the complex signaling pathways between epithelial and mesenchymal cells crucial for hair follicle morphogenesis, highlighting the Wnt pathway's role as a master regulator without reporting new experimental findings.
28 citations
,
December 2012 in “The American Journal of Cosmetic Surgery” This study reported that treatments using ADSC-CM improved hair growth in all participants, with the most pronounced results after four sessions within three to four months.
98 citations
,
October 2012 in “Dermatologic Clinics” This article reviews the impact of nutritional deficiencies on hair health, detailing how they can cause structural abnormalities, pigmentation changes, or hair loss; it presents no new clinical findings.
101 citations
,
August 2010 in “PLoS ONE” In this mouse study, severe selenoprotein deficiency in epidermal cells was linked to skin abnormalities, disrupted hair follicle development, and progressive alopecia, highlighting the role of selenoproteins in skin and hair health.
100 citations
,
April 2010 in “Expert Opinion on Pharmacotherapy” This article reviews existing treatments for male-pattern hair loss, noting that while they can slow progression, they generally achieve only partial hair regrowth.
7 citations
,
January 2009 in “BMJ Case Reports” This report describes a rare case of a non-small-cell lung cancer patient experiencing hair changes after prolonged gefitinib treatment, potentially linked to EGFR inhibition, with limited understanding of its cause.
37 citations
,
February 2008 in “PubMed” This article reviews radiation-induced cicatricial alopecia and suggests that controlling radiation dose depth could potentially prevent this condition.
7 citations
,
July 2007 in “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy” This case report documents a woman with HIV who developed severe hair loss after starting lopinavir-ritonavir, which improved upon switching to a different antiretroviral drug.
39 citations
,
July 2007 in “Archives of Pharmacal Research” A tripeptide-copper complex may help hair grow by increasing cell growth and decreasing cell death.
165 citations
,
December 2004 in “Differentiation” This review discusses the critical role of BMP signaling in the development and regulation of skin and hair follicles and notes that further research could aid therapeutic advances; it presents no new clinical results.
305 citations
,
December 2000 in “The EMBO Journal” Inhibiting Bmp signaling disrupts hair growth and differentiation.
79 citations
,
March 1999 in “The journal of investigative dermatology/Journal of investigative dermatology” This study found that procyanidin oligomers, particularly dimers and trimers, significantly promoted hair growth in mice and hair epithelial cell cultures, suggesting potential use as hair growth agents.
3 citations
,
January 1996 in “Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy” In this study, a 33-year-old HIV-infected man experienced alopecia areata after beginning zidovudine therapy, which reversed upon discontinuation.
147 citations
,
April 1994 in “Drug Safety” Some drugs can cause hair loss or increase hair growth, but these effects are usually reversible when the drug is stopped.
